PMC:4928686 / 14060-14702 JSONTXT

{"project":"2_test","denotations":[{"id":"25788396-17922387-121220515","span":{"begin":206,"end":208},"obj":"17922387"},{"id":"25788396-17922387-121220515","span":{"begin":206,"end":208},"obj":"17922387"},{"id":"25788396-16365468-121220516","span":{"begin":494,"end":496},"obj":"16365468"},{"id":"25788396-16365468-121220516","span":{"begin":494,"end":496},"obj":"16365468"},{"id":"25788396-17922387-68933196","span":{"begin":206,"end":208},"obj":"17922387"},{"id":"25788396-17922387-68933196","span":{"begin":206,"end":208},"obj":"17922387"},{"id":"25788396-16365468-68933197","span":{"begin":494,"end":496},"obj":"16365468"},{"id":"25788396-16365468-68933197","span":{"begin":494,"end":496},"obj":"16365468"}],"text":"Probably the most effective way to answer the question of whether CMV reactivation is pathogenic or merely a bystander in human disease will be properly controlled randomized trials with antiviral therapy [57]. In the case of immune-suppressed transplant patients, CMV was perceived as a definite pathogen, and this led to widespread antiviral use when such agents became available. It was not until decades later that properly controlled trials in immune-suppressed patients proved a benefit [58]. Fortunately, there has been a more circumspect and deliberate approach to antiviral treatment in critically ill patients with CMV reactivation."}